We use cookies on our website. Carry on browsing if you’re happy with this or find out more



Kymab statement on UK Court of Appeal’s decision

Kymab statement on the UK Court of Appeal’s decision regarding the validity of Regeneron’s UK Velocimmune Patents

Cambridge, 28 March 2018: Kymab Limited, a leading human monoclonal antibody biopharmaceutical company, announces that the UK Court of Appeal in London has held that two patents (European Patent EP(UK) 1 360 287 and EP(UK) 2 264 163) owned by Regeneron are valid, thereby overturning the decision of the High Court trial judge, Mr Justice Henry Carr, issued on 1 February 2016 to revoke these patents.

Kymab is disappointed with the Court of Appeal’s decision issued on the 28 March 2018 and will seek leave to appeal the decision to the UK Supreme Court.

Find out which events we'll be attending this year

View events